Quantcast

Latest Disease-modifying antirheumatic drug Stories

2011-02-02 09:59:02

(Ivanhoe Newswire) -- Patients with rheumatoid arthritis, a crippling disease that eats away at the joints and causes severe pain and swelling, aren't receiving their much-needed, low-cost drugs that prevent deformity. Despite medical guidelines recommending that patients receive early and aggressive treatment for rheumatoid arthritis with these medications, only 63 percent of Medicare-managed care patients diagnosed with the disease received any amount of the prescription drugs, according to...

2011-01-27 14:16:13

In rheumatoid arthritis patients unresponsive to biologic agents In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied. In contrast to the prior study,...

2010-11-23 12:53:44

Delay in assessment by rheumatologist increases risk of joint destruction, decreases remission chances Positive outcomes in rheumatoid arthritis (RA) are closely linked to early diagnosis and treatment with disease-modifying antirheumatic drugs (DMARDs). A study by researchers in the Netherlands found that patients who are assessed by rheumatologists soon after RA symptoms appear are more likely to experience less joint destruction and improved chances of DMARD-free disease remission. Details...

2010-11-09 07:05:00

ATLANTA, Nov. 9, 2010 /PRNewswire/ -- The addition of Cimzia® (certolizumab pegol; CZP) to current therapy was associated with a rapid clinical response, improved function and reduced disease activity in a diverse group of adult rheumatoid arthritis (RA) patients reflecting those seen in daily clinical practice (including those with prior TNF-inhibitor use). These positive clinical trial data were presented during the American College of Rheumatology's (ACR) 2010 Annual...

2010-10-05 07:00:00

BURLINGTON, Mass., Oct. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed rheumatologists and dermatologists expect they will increase their use of Centocor Ortho Biotech's Simponi as a first-line disease-modifying antirheumatic drug (DMARD) by the end of 2014 for the treatment of psoriatic arthritis. According to the new report entitled Treatment Algorithms in Psoriatic Arthritis,...

2010-09-29 06:30:00

SOUTH SAN FRANCISCO, Calif., Sept. 29 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by...

2010-09-28 19:04:52

Study shows biologic agents can be reserved for treatment-resistant patients A study conducted at Copenhagen University Hospital showed that treatment of rheumatoid arthritis (RA) with disease modifying antirheumatic drugs (DMARDs), glucocorticoids, biologic agents, or a combination of agents significantly reduced radiographic evidence of joint destruction, with a relative effect of 48%󈞴% as compared with placebo. A direct comparison between the...

2010-09-15 11:55:00

BURLINGTON, Mass., Sept. 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of rheumatoid arthritis (RA), 44 percent of surveyed rheumatologists who expect to prescribe Genmab/GlaxoSmithKline's Arzerra say they will prescribe Arzerra before Biogen Idec/Roche/Chugai/Zenyaku Kogyo's Rituxan. Only 22 percent of surveyed rheumatologists who do not expect to prescribe Arzerra...

2010-08-13 14:53:20

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative New criteria for rheumatoid arthritis (RA), published in the Annals of Rheumatic Diseases, could prevent thousands of people from developing disabling late stage disease, by redefining how RA should be classified. Rheumatoid arthritis is a progressive autoimmune inflammatory disease, primarily of the joints. If untreated, it leads to damage of bone...

2010-06-24 13:57:14

Disease-modifying antirheumatic drugs (DMARDs) should be used early and aggressively at the first sign of rheumatoid arthritis (RA). The results of an 11-year trial, published in BioMed Central's open access journal Arthritis Research & Therapy, demonstrate that active treatment from the very beginning pays off, even in the long run. Dr Vappu Rantalaiho, from Tampere University Hospital, Finland, worked with a team of researchers to study radiologic progression in 195 patients with RA....


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.